Patents Assigned to Cytogen Corporation
-
Patent number: 7279548Abstract: Novel polypeptides having WW domains of interest are described, along with DNA sequences that encode the same. A method of identifying these polypeptides by means of a sequence-independent (that is, independent of the primary sequence of the polypeptide sought), recognition unit-based functional screen is also disclosed. Various applications of the method and of the polypeptides identified are described, including their use in assay kits for drug discovery, modification, and refinement.Type: GrantFiled: June 28, 2002Date of Patent: October 9, 2007Assignees: Cytogen Corporation, The University of North Carolina at Chapel HillInventors: Gregorio Pirozzi, Brian K. Kay, Dana M. Fowlkes
-
Patent number: 7223547Abstract: Novel polypeptides having functional domains of interest are described, along with DNA sequences that encode the same. A method of identifying these polypeptides by means of a sequence-independent (that is, independent of the primary sequence of the polypeptide sought), recognition unit-based functional screen is also disclosed. Various applications of the method and of the polypeptides identified are described, including their use in assay kits for drug discovery, modification, and refinement.Type: GrantFiled: March 23, 2004Date of Patent: May 29, 2007Assignees: Cytogen Corporation, University of North Carolina at Chapel HillInventors: Andrew B. Sparks, Noah Hoffman, Brian K. Kay, Dana M. Fowlkes, Stephen J. McConnell
-
Patent number: 7135457Abstract: This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.Type: GrantFiled: May 15, 1998Date of Patent: November 14, 2006Assignees: Cytogen Corporation, Elan Corporation, PLCInventors: Vernon L. Alvarez, Daniel J. O'Mahony, Imelda J. Lambkin, Catherine A. Patterson, Judith Singleton, Benjamin A. Belinka, Jr., John M. Carter, Gerard M. Cagney
-
Patent number: 7053177Abstract: This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastrointestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.Type: GrantFiled: May 15, 1998Date of Patent: May 30, 2006Assignee: Cytogen CorporationInventors: Vernon L. Alvarez, Daniel J. O'Mahony, Imelda J. Lambkin, Catherine A. Patterson, Judith Singleton, Benjamin A. Belinka, Jr., John M. Carter, Gerard M. Cagney
-
Publication number: 20040229289Abstract: Abtides are provided. Abtides are peptides identified by a two-step process of screening random peptide libraries. In the first step, the target ligand is an antibody or receptor (or derivative thereof). The peptides identified in the first screening step are used as target ligands in the second screening step. The peptides identified in the second screening step are abtides. Abtides possess binding specificities that are similar to the binding specificities of the antibodies or receptors that are used in the first screening step. Abtides may be used in place of antibodies in many assays or therapeutic applications.Type: ApplicationFiled: April 28, 2004Publication date: November 18, 2004Applicant: Cytogen CorporationInventor: Vernon L. Alvarez
-
Patent number: 6703362Abstract: This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.Type: GrantFiled: May 15, 1998Date of Patent: March 9, 2004Assignees: Cytogen Corporation, Elan Corporation, PLCInventors: Vernon L. Alvarez, Daniel J. O'Mahony, Imelda J. Lambkin, Catherine A. Patterson, Judith Singleton, Benjamin A. Belinka, Jr., John M. Carter, Gerard M. Cagney
-
Patent number: 6432920Abstract: Peptides having general and specific binding affinities for the Src homology region 3 (SH3) domains of proteins are disclosed in the present invention. In particular, SH3 binding peptides have been isolated from phage-displayed random peptide libraries which had been screened for isolates that bind to bacterial fusion proteins having an SH3 domain and glutathione S-transferase (GST). Preferred peptides are disclosed which comprise a core 7-mer sequence (preferably, a consensus motif) and two or more, preferably at least six, additional amino acid residues flanking the core sequence, for a total length of 9, preferably at least 13, amino acid residues and no more than about 45 amino acid residues. Such peptides manifest preferential binding affinities for certain SH3 domains. The preferred peptides exhibit specific binding affinities for the Src-family of proteins. In vitro and in vivo results are presented which demonstrate the biochemical activity of such peptides.Type: GrantFiled: February 8, 2000Date of Patent: August 13, 2002Assignees: Cytogen Corporation, University of North Carolina at Chapel HillInventors: Andrew B. Sparks, Brian K. Kay, Judith M. Thorn, Lawrence A. Quilliam, Channing J. Der, Dana M Fowlkes, James E Rider
-
Patent number: 6015561Abstract: Abtides are provided. Abtides are peptides identified by a two-step process of screening random peptide libraries. In the first step, the target ligand is an antibody or receptor (or derivative thereof). The peptides identified in the first screening step are used as target ligands in the second screening step. The peptides identified in the second screening step are abtides. Abtides possess binding specificities that are similar to the binding specificities of the antibodies or receptors that are used in the first screening step. Abtides may be used in place of antibodies in many assays or therapeutic applications.Abtides binding to polymorphic epithelial mucin (PEM) are provided.Also provided are methods of obtaining abtides as well as diagnostic and therapeutic compounds containing abtides.Type: GrantFiled: March 22, 1999Date of Patent: January 18, 2000Assignee: Cytogen CorporationInventor: Vernon L. Alvarez
-
Patent number: 5942210Abstract: This invention relates to lyoprotection agents for protecting macromolecules during lyophilization or freeze-drying. In particular, methods for use of these lyoprotectants in conjugate formulations are disclosed. Additionally, this invention describes lyophilized instant kit formulations for the radiolabeling of pharmaceuticals and/or macromolecules.Type: GrantFiled: November 15, 1994Date of Patent: August 24, 1999Assignee: Cytogen CorporationInventors: Michiel E Ultee, Charlotte A Burton
-
Patent number: 5885577Abstract: Abtides are provided. Abtides are peptides identified by a two-step process of screening random peptide libraries. In the first step, the target ligand is an antibody or receptor (or derivative thereof). The peptides identified in the first screening step are used as target ligands in the second screening step. The peptides identified in the second screening step are abtides. Abtides possess binding specificities that are similar to the binding specificities of the antibodies or receptors that are used in the first screening step. Abtides may be used in place of antibodies in many assays or therapeutic applications.Abtides binding to polymorphic epithelial mucin (PEM) are provided.Also provided are methods of obtaining abtides as well as diagnostic and therapeutic compounds containing abtides.Type: GrantFiled: June 7, 1995Date of Patent: March 23, 1999Assignee: Cytogen CorporationInventor: Vernon L. Alvarez
-
Patent number: 5763202Abstract: Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to human prostate epithelial cells and normal prostatic epithelial cells. The monoclonal antibodies, specifically, 7Ell monoclonal antibodies, can be used diagnostically and therapeutically.Type: GrantFiled: June 7, 1995Date of Patent: June 9, 1998Assignee: Cytogen CorporationInventor: Julius S. Horoszewicz
-
Patent number: 5609847Abstract: The invention relates to a method of treating a patient in need thereof, including a need for diagnosis or treatment, comprising the administration of a metal complex of a polypeptide construct. The construct comprises a compound of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone,"P" is a polypeptide capable of targeting particular-cells, tissues or organs of the body,"A" may be the group --NR'--NR"-- or the group --NR'--NR"--L-- in which L may be an aliphatic or aromatic linker group,R, R', and R" may be the same or different and may be hydrogen or an aliphatic group,m is an integer .gtoreq.2, provided that the groups R, R', R", L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain,n is an integer .gtoreq.0;or a pharmaceutically acceptable salt thereof. The constructs of the present invention are capable of binding a variety of metallic species.Type: GrantFiled: June 7, 1995Date of Patent: March 11, 1997Assignee: Cytogen CorporationInventors: Benjamin A. Belinka, Jr., Daniel J. Coughlin, Vernon L. Alvarez, Richard Wood
-
Patent number: 5593656Abstract: This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone, "P" is a polypeptide capable of targeting particular cells, tissues or organs of the body, "A" may be the group --NR'--NR"-- or the group --NR'--NR"--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R" may be the same or different and may be hydrogen or an aliphatic group, m is an integer.gtoreq.2, provided that the groups R, R', R", L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain, n is an integer.gtoreq.Type: GrantFiled: June 7, 1995Date of Patent: January 14, 1997Assignee: Cytogen CorporationInventors: Benjamin A. Belinka, Jr., Daniel J. Coughlin, Vernon L. Alvarez, Richard Wood
-
Patent number: 5585468Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, substantial thioureas for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.Type: GrantFiled: June 27, 1994Date of Patent: December 17, 1996Assignee: Cytogen CorporationInventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.
-
Patent number: 5578288Abstract: This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone, "P" is a polypeptide capable of targeting particular cells, tissues or organs of the body, "A" may be the group --NR'--NR"-- or the group --NR'-- NR"--L-- in which L may be an aliphatic or aromatic linker group, R, R', and R" may be the same or different and may be hydrogen or an aliphatic group, m is an integer.gtoreq.2, provided that the groups R, R', R", L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain, n is an integer.gtoreq.Type: GrantFiled: June 7, 1995Date of Patent: November 26, 1996Assignee: Cytogen CorporationInventors: Benjamin A. Belinka, Jr., Daniel J. Coughlin, Vernon L. Alvarez, Richard Wood
-
Patent number: 5578484Abstract: Monoclonal antibodies, specifically 9H10-A4 monoclonal antibodies, specific to an epitope present on the surface of LNCaP cells, are produced by hybridoma cell line 9H10-A4 formed by fusing mouse lymphocytes and mouse myeloma cells. 9H10-A4 monoclonal antibodies are useful to positively identify LNCaP cells and distinguish them from other cultured cells, and as a reliable control in competitive binding studies for detection of circulating antigens associated with prostate carcinoma.Type: GrantFiled: September 16, 1994Date of Patent: November 26, 1996Assignee: Cytogen CorporationInventor: Julius S. Horoszewicz
-
Patent number: 5527885Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, isothiocyanate derived thiocarbonyls for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.Type: GrantFiled: June 30, 1994Date of Patent: June 18, 1996Assignee: Cytogen CorporationInventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.
-
Patent number: 5495042Abstract: A process for the purification of aminophosphonic acids under non-alkaline conditions is described. In particular, aminophosphonic acids are slurred in neutral or acidic water, heated to reflux, cooled and then filtered. Product purities approaching 100% are thus obtained.Type: GrantFiled: November 4, 1993Date of Patent: February 27, 1996Assignee: Cytogen CorporationInventors: Benjamin A. Belinka, Jr., Daniel J. Coughlin
-
Patent number: 5449761Abstract: This invention relates to the preparation and use of novel open-chain or cyclic polypeptide constructs in which two or more polypeptide chains, in an open-chain construct, or one or more chains, in a cyclic construct, are chemically derivatized such that the resulting construct exhibits both metal-binding capability and tissue-, organ- or cell-targeting selectivity. In particular, the polypeptide constructs of the present invention comprise compounds of the formula (I): ##STR1## in which, "B" is a hydrocarbon backbone, "P" is a polypeptide capable of targeting particular cells, tissues or organs of the body, "A" may be the group --NR'--NR"-- or the group --NR'--NR"--L-- in which L may be an aliphatic or aromatic linker group, R, R' and R" may be the same or different and may be hydrogen or an aliphatic group, m is an integer .gtoreq.2, provided that the groups R, R', R', L and "P" of a given chain may be the same or different from the groups R, R', R", L and "P" of another chain, n is an integer .gtoreq.Type: GrantFiled: September 28, 1993Date of Patent: September 12, 1995Assignee: Cytogen CorporationInventors: Benjamin A. Belinka, Jr., Daniel J. Coughlin, Vernon L. Alvarez, Richard Wood
-
Patent number: 5326856Abstract: This invention relates to chelating agents useful for coupling metal ions to biologically active molecules. In particular, isothiocyanate derived thiocarbonyls for chelating metals such as technetium are provided that can be conjugated to a targeting molecule such as an antibody, a peptide or a protein.Type: GrantFiled: April 9, 1992Date of Patent: July 5, 1994Assignee: Cytogen CorporationInventors: Daniel J. Coughlin, Benjamin A. Belinka, Jr.